ClinConnect ClinConnect Logo
Search / Trial NCT06888570

Relationship Between Eating Patterns, Body Composition and the Detection of Fatty Liver in Children and Adolescents with Trisomy 21: LiverTy Project

Launched by IMDEA FOOD · Mar 14, 2025

Trial Information

Current as of April 23, 2025

Active, not recruiting

Keywords

Fibroscan Fatty Liver Disease Body Composition Trisomy 21 Down Syndrome Kidmed Questionnaire 24 Hour Dietary Recall Non Invasive Liver Assessment Non Alcoholic Fatty Liver Diseases Obesity Prevention Children Adolescents

ClinConnect Summary

The LiverTy Project is a clinical trial that aims to understand how eating habits and body composition are related to liver health in children and adolescents with Down syndrome (also known as trisomy 21). The study focuses on a concern called non-alcoholic fatty liver disease (NAFLD), which is when fat builds up in the liver without any alcohol use. This condition is more common in individuals with Down syndrome and can lead to serious liver problems if not detected early. Researchers will use non-invasive methods, like liver elastography (a type of ultrasound that measures liver fat and stiffness), along with dietary assessments, to evaluate the risk of NAFLD in participants.

To be eligible for this study, children and young adults aged 5 to 22 years with a diagnosis of Down syndrome or a similar genetic intellectual disability can participate, provided they have a body mass index (BMI) between 17 and 40. Participants will undergo various assessments to check their liver health, body composition, and eating habits over a 24-hour period. This study is essential for identifying how obesity and diet can affect liver health in this population, allowing for earlier interventions if needed.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Children (5-10 years), and adolescents (11-19) andyoung adults (20-22 years) of bothSexes
  • 5 to 22 years old
  • Diagnosis of trisomy 21 or other intellectual disability of genetic origin for the group of the cases.
  • BMI: 17-40 Kg/m2
  • Signing of the informed consent by the parents or guardians.
  • Exclusion Criteria:
  • Not meeting the inclusion criteria
  • Have previous liver pathology.
  • Be under any medical treatment that
  • Modify composition parameters Body: GLP-1 analogues and derivatives.

About Imdea Food

IMDEA Food is a leading research institute dedicated to advancing knowledge in the field of food science and nutrition. Based in Madrid, Spain, it focuses on promoting health and well-being through innovative research and development. The institute collaborates with academic, industrial, and governmental partners to address critical issues related to food quality, safety, and sustainability. IMDEA Food is committed to conducting high-quality clinical trials that contribute to evidence-based practices in nutrition and public health, ultimately aiming to improve dietary habits and health outcomes across populations.

Locations

Madrid, , Spain

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported